Acute Effects of Transdermal 17β-Estradiol on Hemostatic Variables after 24-hour Treatment

Abstract

The aim of this study was to investigate the acute effects of transdermal 17β-estradiol (Estraderm®) on plasma levels of coagulatory and fibrinolytic factors in postmenopausal normotensive and hypertensive women. Eleven normotensive and 13 hypertensive women were included in this placebo-controlled crossover study. In a randomized order each subject was treated with a patch of 100 yig 17β-estradiol or placebo for 24 hours. Serum levels of tissue type plasminogen activator (tPA) activity, plasminogen activator inhibitor I (PAI-1) activity, tPA antigen, PAI-I antigen, FVII, FX, and fibrinogen were assayed after both treatments. There was no significant difference in serum levels of hemostatic variables after treatment with estrogen compared to levels after placebo treatment in either of the groups. Nor was there any measurable difference when comparing hypertensive and normotensive subjects.

Keywords

Estrogen Hypertension Coagulation/fibrinolysis

References

1. Burt VL , Whelton P , Roccella EJ , et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991 [see comments]. Hypertension 1995;25:305-305.

2. Tepper R , Goldberger S , May JY , Luz IJ , Beyth Y. Hormonal replacement therapy in postmenopausal women and cardiovascular disease: An overview. Obstet Gynecol Surv 1992;7:426-426.

3. Juhan-Vague I , Pyke SD , Alessi MC , et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectorls. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities [see comments]. Circulation 1996;94:2057-2057.

4. Montalescot G , Collet JP , Choussat R , Thomas D. Fibrinogen as a risk factor for coronary heart disease. Eur HeartJ 1998;19(Suppl H)H11-H11.

5. Meade TW , Mellows S , Brozovic M , et al. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study [see comments]. Lancet 1986;2:533-533.

6. Makris TK , Tsoukala C , Krespi P , et al. Haemostasis balance disorders in patients with essential hypertension. Thromb Res 1997;88:99-99.

7. van Wersch JW , Rompelberg-Lahaye J , Lustermans FA . Plasma concentration of coagulation and fibrinolysis factors and platelet function in hypertension. Eur J Clin Chem Clin Biochem 1991;29:375-375.

8. Poli KA , Tofler GH , Larson MG , et al. Association of blood pressure with fibrinolytic potential in the Framingham offspring population [see comments]. Circulation 2000; 101:264-264.

9. Grodstein F , Stampfer MJ , Colditz GA , et al. Postmenopausal hormone therapy and mortality [see comments]. N Engl J Med. 1997;336:1769-1769.

10.

10. Hulley S , Grady D , Bush T , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group [see comments]. JAMA 1998;280:605-605.

11.

11. Lip GY , Beevers M , Churchill D , Beevers DG . Hormone replacement therapy and blood pressure in hypertensive women. J Hum Hypertens 1994:8:491-491.

12.

12. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. [see comments] [published erratum appears in JAMA 1995;274(21):1676]. JAMA 1995;273:199-199.

13.

13. Manhem K , Ahlm H , Milsom I , Svensson A. Transdermal oestrogen reduces daytime blood pressure in hypertensive women [see comment]. J Hum Hypertens 1998;12:323-323.

14.

14. Gebara OC , Mittleman MA , Sutherland P , et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995;91:1952-1952.

15.

15. Gebara OC , Mittleman MA , Walsh BW , et al. Fibrinolytic potential is significantly increased by oestrogen treatment in postmenopausal women with mild dyslipidaemia. Heart 1998;80:235-235.

16.

16. Andersen LF , Gram J , Skouby SO , Jespersen J. Effects of hormone replacement therapy on hemostatic cardiovascular risk factors. Am J Obstet Gynecol 1999;180:283-283.

17.

17. Scarabin PY , Alhenc-Gelas M , Plu-Bureau G , Taisne P , Agher R , Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997;17:3071-3071.

18.

18. Kroon UB , Tengborn L , Rita H , Backstrom AC . The effects of transdermal oestradiol and oral progestogens on haemostasis variables. Br J Obstet Gynaecol 1997;104 (Suppl 16):32-32.

19.

19. Winkler UH . Hormone replacement therapy and hemostasis: Principles of a complex interaction. Maturitas 1996; 24:131-131.

20.

20. Wall U , Jern C , Jern S. High capacity for tissue-type plasminogen activator release from vascula endothelium in vivo. J Hypertension 1997;17:3376-3376.